We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.
More patient informationFind answers to some of your most frequently asked questions
New methods and reliable tests to help deliver personalised treatment
RGCC CAMBISeq (cancer analysis, mutational burden and instability sequencing) provides next generation sequencing analysis on both DNA and RNA to help predict a patient’s response to immunotherapy and to detect variants.
This test identifies chromosomal abnormalities – when either part of the genetic sequence in a chromosome is deleted or added to – that might lead to cancer. It uses a technique called array CGH to identify abnormalities in a genome more clearly than traditional microscopes can. These abnormalities could be linked with parts of regions […]
This test focuses on the status of a patient’s immune system. The test uses specific cellular markers, and the production of proteins called cytokines, to detect the type or types of cells that are responsible for switching a patient’s immune system on and off. Immune-Frame uses two different assays: the ELISA assay is used to […]
This test provides information, based on the detection of circulating tumour cells, about whether and where the tumour is likely to spread. Studies show that the cancer cells that have the potential to spread from the primary tumour express specific genes and proteins, or markers. These markers vary according to the organ that the tumour […]
This test relies on pharmacogenomics. This is the science of inherited variations in genes, how these inherited variations dictate a patient’s response to a drug, and the ways these variations can be used to predict whether a patient will have a good or bad response to a drug, or no response at all. ChemoSNiP tests […]
This test provides information about the efficacy of natural biological substances or extracts on circulating tumour cells. Onconomics Extracts focuses on testing using three methods: testing for the direct effect of an anti-cancer treatment, stimulating the immune system and inhibiting proliferative signals in the cancer cells that stimulate them to grow.
This test provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. Onconomics Plus RGCC is based on three methods: testing for the direct effect […]
This test provides information about the effect of specific anti-cancer drugs and targeted therapies on a single patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays.
This test provides information about the presence of circulating tumour cells, their concentration, and immunophenotype for specific types of malignancies. This test is a tailor-made test for certain cancers: such as breast cancer (for which we provide the Oncotrail RGCC for breast cancer) and prostate cancer (for which we provide Oncotrail RGCC for prostate cancer. […]
This test provides information about the presence of circulating tumour cells, and their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.
This test detects the presence of circulating tumour cells, and measures their concentration in the blood. As these cells that could lead to the recurrence of a cancer, this test is useful to detect relapse early, and as a follow-up tool.
Find out more about our latest research, trials and education days
More evidence is emerging to support the use of testing for circulating tumour DNA (ctDNA) as a promising way to predict whether a cancer will come back. Tumours release degraded fragments of DNA, including ctDNA, into the bloodstream. Testing a cancer patient’s blood for this DNA, using a type of blood test called a liquid […]
In the future, liquid biopsy testing is likely to play an increasing role in identifying which patients with colorectal cancer are most likely to have their cancer come back again after surgery. Liquid biopsy testing could also help doctors to decide which treatments would be most suitable to recommend to individual patients, according to new […]
We are happy to announce that we contributed to iGem Thessaloniki team’s won of the top prize in the international iGEM Synthetic Biology competition 2019, organized by MIT University in Boston. The project is called “POSEIDON” and it is a toolkit for the examination of DNA-Protein interactions. IGem team of Thessaloniki deploys the first DNA […]
CIMI -International Congress of Integrative Medicine -Understanding Patient Individuality and Building a Therapeutic Path, November 2019 – Brazil, Uberlandia
